Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
67 Leser
Artikel bewerten:
(0)

EBD Group to announce the Johnson & Johnson Innovation Startup Day competition grand prize winner at BioPharm America' 2015 Partnering Event

Leaders in life sciences to gather in Boston September 15-17 for partnering event

CARLSBAD, California and BOSTON, Sept. 2, 2015 /PRNewswire/ --BioPharmAmerica' 2015 life science partnering event will take place in Boston September 15-17 at the Boston Marriott Copley Place. The event will convene members of the global life science community to forge connections among startups, entrepreneurs and the drug development industry.

A pitch contest for startup and young companies will take place in the afternoon duringBiotech Startup Day on Wednesday, September 16. A panel of judges will choose a winner of this open-mic session from among 20 pre-selected Startup Day applicants, and the winner will receive a presentation slot and complimentary full access registration to the 2016 BioPharma America event.

Entrepreneurs participating in Biotech Startup Day also may be eligible to compete for a grand prize being awarded through the Johnson & Johnson Innovation Startup Day competition. The winner of this competition will have the opportunity to gain access to the use of one bench at a Johnson & Johnson Innovation, JLABS location for three months and six months of mentorship from a Johnson & Johnson Innovation team member. For specific eligibility requirements and application materials please visit the online information page.

Biotech Startup Day is a dedicated day at BioPharm America that is specifically designed to provide early-stage projects and young companies the opportunity to get on the radar of the global life science community through presentations and partnering meetings with Boston's leading financiers, pharma dealmakers and biotech business key opinion leaders.

The live pitch contest will be moderated by Doug MacDougall, President of MacDougall Biomedical Communications, and the judging panel includes:

  • Jeffrey Arnold - Member, Mass Med Angels and Boston Harbor Angels
  • Thomas Luby - Senior Director, New Ventures, Johnson and Johnson Innovation, Boston
  • Ivana Magovcevic-Liebisch - Senior VP and Head of Global Business Development, Teva Pharmaceuticals
  • Jason Rhodes - Partner, Atlas Venture
  • S. Edward Torres - Co-Founder and Managing Director, Lilly Ventures

Register now and plan your Boston week this September 15-17. The deadline to submit your Biotech Startup Day registration for consideration is Tuesday, September 8, 2015. All awards will be announced onsite at Biotech Startup Day on Wednesday, September 16, 2015.

Partnering at BioPharm America is facilitated by partneringONE®, the gold standard one-to-one networking solution for the life sciences.

Additional links and information:

Follow BioPharm America 2015 on Twitter: @EBDGroup (hashtag: BPA15). Engage with Biotech Startup Day at BioPharm America by using the hashtag BPAStartupDay.

Online Press Kit service for BioPharm America' 2015 is available from PR Newswire to enhance your public relations efforts.

About EBD Group

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group's conferences are run with the support of leading corporations and international trade associations and include:

  • BIO-Europe® and BIO-Europe Spring®
  • BioPharm America'
  • Biotech Showcase'
  • BioEquity Europe
  • ChinaBio® Partnering Forum
  • Medtech Partnering Forum
  • Biolatam®

EBD Group's sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.

EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.

EBD Group has offices in the USA and Europe.

For more information please visit www.ebdgroup.com.

© 2015 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.